Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Probucol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 4/20 | 0.75 |
| ▸ | HPN | P05981 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.75 |
| ▸ | VCAM1 | P19320 | 13/20 | 0.57 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Probucol SCHEMBL4150 | 0.87 | HPN (1.00) | ALOX15HPNMAPTSIRT5VCAM1 | |
| Probucol SCHEMBL5143451 | 0.87 | HPN (1.00) | ALOX15HPNMAPTSIRT5VCAM1 | |
| SCHEMBL12042584 | 0.85 | ALOX15 (0.68) | ALOX15HPNMAPTSIRT5VCAM1 | |
| Probucol SCHEMBL8344652 | 0.85 | ALOX15 (0.95) | ALOX15HPNMAPTSIRT5VCAM1 | |
| Probucol SCHEMBL4620631 | 0.85 | ALOX15 (0.95) | ALOX15HPNMAPTSIRT5VCAM1 | |
| Probucol SCHEMBL7051742 | 0.80 | ALOX15 (0.60) | ALOX15HPNMAPTSIRT5VCAM1 | |
| SCHEMBL12791592 | 0.79 | ALOX15 (0.84) | ALOX15HPNMAPTSIRT5VCAM1 | |
| SCHEMBL4985953 | 0.79 | HPN (0.84) | ALOX15HPNMAPTSIRT5VCAM1 | |
| Butylated Hydroxytoluene SCHEMBL20982068 | 0.79 | ALDH1A1 (0.72) | ALOX15HPNMAPTSIRT5CA2 | |
| Butylated Hydroxytoluene SCHEMBL11647738 | 0.79 | ALDH1A1 (0.72) | ALOX15HPNMAPTSIRT5CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622604-B2 | via grignard intermediate such as benzylmagnesium chloride and esterification with succinic anhydride; inflammatory and cardiovascular diseases; optimizes the amount of monoester in the final product mixture and minimizes the amount of reagents; e.g. synthesis of succinobucol | SALUTRIA PHARMACEUTICALS LLC (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080009642-A1 | Process of Preparing Esters and Ethers of Probucol and Derivatives Thereof | CRABTREE ACQUISITION CO, LLC | 2008-01-10 | — | — | US | disclosed |
| US-7273948-B2 | Process of preparing esters and ethers of probucol and derivatives thereof | ATHEROGENICS, INC. (US) | 2007-09-25 | — | — | US | disclosed |
| EP-1594824-A4 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS INC (US) | 2007-04-04 | — | — | EP | disclosed |
| US-7166605-B2 | Probucol nitro-derivatives | NICOX, S.A. (FR) | 2007-01-23 | — | — | US | disclosed |
| US-20060167003-A1 | Probucol derivatives | NICOX S.A. (FR) | 2006-07-27 | — | — | US | disclosed |
| EP-1594824-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | Atherogenics, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1521740-A2 | PROBUCOL DERIVATIVES | Nicox S.A. (FR) | 2005-04-13 | — | — | EP | disclosed |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | CRABTREE ACQUISITION CO, LLC | 2004-10-14 | — | — | US | disclosed |
| WO-2004062622-A2 | PROCESS OF PREPARING ESTERS AND ETHERS OF PROBUCOL AND DERIVATIVES THEREOF | ATHEROGENICS, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2003080568-A2 | PROBUCOL DERIVATIVES | NICOX S.A. (FR) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167003-A1 | Probucol derivatives | PNLIP, APOB, LIPC | ALOX15 1129/4885HPN 618/4885MAPT 1126/4885 |
| US-20080009642-A1 | Process of Preparing Esters and Ethers of Probucol and Derivatives Thereof | NR3C2, MGLL, GCG | ALOX15 1829/4885HPN 2326/4885MAPT 1606/4885 |
| US-20040204485-A1 | Process of preparing esters and ethers of probucol and derivatives thereof | NR3C2, MGLL, GCG | ALOX15 1829/4885HPN 2326/4885MAPT 1606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.